“The promising results from Alzinova's phase 1b study mark an important step forward in the development of a potential treatment for Alzheimer's disease. ALZ-101 has shown good safety and tolerability, a high frequency of immune response and also a positive change in biomarkers, which is very encouraging," comments Henrik Zetterberg, professor of neurochemistry at the University of Gothenburg and University College London and scientific advisor to Alzinova.

The abstract entitled "Phase 1b trial on the safety, tolerability and immunogenicity of anti-amyloid vaccine ALZ-101 in subjects with MCI or mild AD" will be presented by Henrik Zetterberg at the prestigious Alzheimer's Association International Conference (AAIC) which is held July 28 – August 1.

“Our data suggest that the antibodies generated by ALZ-101 influence the disease process in Alzheimer's. What is particularly interesting in this context is that, unlike other therapies against Amyloid-beta, ALZ-101 does not target the plaque. So it is likely that the effect comes from another, completely unique, mechanism of action where other toxic forms of Amyloid-beta are targeted", comments Anders Sandberg, Chief Scientific Officer at Alzinova.

The presentation includes the results from the first part (Part A1) of Alzinova's phase 1b study with the vaccine candidate ALZ-101. In the clinical trial, ALZ-101 has shown good safety and tolerability as well as high frequency of immune response. Exploratory endpoints indicate that ALZ-101 generated positive changes in cerebrospinal fluid biomarkers in those patients who exhibited high antibody levels. These changes were already observed after 20 weeks of treatment where ALZ-101 was administered on only 4 occasions.

The abstract and poster will be available after the presentation on Alzinova's website:
https://www.alzinova.com/scientific-presentations/